NCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
Clinical Trials
26 trialsNCT05397093 2026-04-15
ITIL-306 in Advanced Solid Tumors
Instil Bio
Phase 1 Terminated
NCT03786081 2026-04-14
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
Phase 1/2 Terminated
NCT01164150 2026-04-13
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Cancer Trials Ireland
Phase 2 Terminated
NCT05180474 2026-04-13
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
Phase 1/2 Terminated
NCT07000344 2026-04-09
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Phase NA Terminated
NCT07035067 2026-04-07
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
PeriPharm
Terminated
NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT03894215 2026-03-27
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Agenus Inc.
Phase 2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03922776 2026-03-18
TILsOV
Centre Oscar Lambret
Phase NA Terminated
NCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT00421096 2026-03-13
GEMCOL
Centre Oscar Lambret
Phase 2 Terminated
NCT01641484 2026-03-13
ANOXICOL
Centre Oscar Lambret
Phase NA Terminated
NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
NCT05159050 2026-02-25
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
Phase 1 Terminated
NCT06171789 2026-02-25
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT06546553 2026-02-23
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
Phase 1 Terminated
NCT05502367 2026-02-19
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
Antiva Biosciences
Phase 1/2 Terminated
NCT04780945 2026-02-17
FAB
Leiden University Medical Center
Phase 2 Terminated
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT05357027 2026-01-21
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
Phase 1/2 Terminated